... phosphorylation. Consistently, patients with RCC exhibiting low SYNE1 expression, who were treated with the vascular endothelial growth factor receptor inhibitor sunitinib, had worse progression-free survival. Conclusions: The results indicate that the expression of SYNE1 /Nesprin1 and SYNE1 mutations in patients...

... and drug resistance in some cancers. However, the expression and biological role of miR-130b in renal cell carcinoma (RCC) remain poorly understood. This study aimed to examine the expression and functional role of miR-130b and to analyze the association between miR-130b and sunitinib resistance in RCC...

... refused systemic chemotherapy and received targeted therapies with sunitinib (37.5 mg/day, 5 patients) or the mammalian target of rapamycin (mTOR) inhibitor everolimus (10 mg/day, 1 patient) as the first-line treatment. We evaluated the drugs' toxicities and survival. The median age of the patients was 55...

...Camillo Porta; Chiara Paglino; Ilaria Imarisio; Carlo Ganini; Lucia Sacchi; Silvana Quaglini; Vania Giunta; Mara De Amici Objectives: This study included a cohort of advanced renal cell carcinoma patients treated with sunitinib. Since resistance to sunitinib may be mediated through angiogenic...

... kinase inhibitors (rTKIs) sorafenib and sunitinib in metastatic renal cell cancer. Methods: We performed a retrospective analysis of patients who had received sequential therapy with both rTKIs and integrated these results into a pooled analysis of available data from other publications. Differences...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Treatment duration Renal cell carcinoma Tyrosine-kinase inhibitor Sunitinib Targeted therapy First-line treatment Targeted therapies, directed against tumour...

...Hyo Song Kim; Min Hee Hong; Kiyeol Kim; Sang-Joon Shin; Joong-Bae Ahn; Hei Chul Jeung; Hyun Cheol Chung; Youngil Koh; Se-Hoon Lee; Yung-Jue Bang; Sun Young Rha Objective: We aimed to describe the efficacy and safety of sunitinib in unselected Korean advanced renal cell carcinoma (RCC) patients...

...Marcus Alexander Wörns; Marcus Schuchmann; Christoph Düber; Gerd Otto; Peter Robert Galle; Arndt Weinmann Objective: To evaluate the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) after progression under sorafenib treatment. Methods: Sunitinib...

... treatment. Sunitinib is approved for treatment of a GIST after disease progression on, or intolerance to, imatinib therapy. Progression may occur early or later on, in treatment and is determined by factors including initial GIST genotype and mutational status. GISTs with KIT exon 11 mutations appear...

... inhibitor class of novel targeted therapies, including sorafenib and sunitinib, has emerged as an important cause of HFS, with 10–28% of patients treated with sunitinib and 10–62% of patients treated with sorafenib reporting HFS. This review examines the epidemiology, clinical features, histopathology...

...Bohuslav Melichar For many years, therapy for metastatic renal cell carcinoma (mRCC) was limited to a single line of cytokine therapy with either interferon or interleukin-2. Relatively recently, the novel targeted agents bevacizumab, sorafenib, sunitinib and temsirolimus have each demonstrated...

...Kaja Zimmermann; Alexander Schmittel; Ursula Steiner; Anne Marie Asemissen; Maren Knoedler; Eckhard Thiel; Kurt Miller; Ulrich Keilholz Background: Sorafenib and sunitinib are tyrosine kinase inhibitors with largely overlapping specificities, approved for the treatment of metastatic renal-cell...

...Edwin Herrmann; Stefan Bierer; Joachim Gerss; Thomas Köpke; Lothar Hertle; Christian Wülfing Objectives: It was the aim of this study to investigate the clinical differences between the tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib as second-line treatment for cytokine-refractory kidney...